# ACUTAAS (ACUTAAS) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/acutaas

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹3,443.1
- Change: +3.86%
- As of: 2026-09-18
- 1D return: +3.78%
- 5D return: -0.32%
- 1M return: +7.16%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, ACUTAAS is trading at ₹3440.3, showing a mixed technical picture across different timeframes. The daily timeframe indicates a bearish Super Trend signal, with the price below this indicator, despite the price being above key moving averages like the 20-day and 50-day Exponential Moving Averages (EMAs) and Simple Moving Averages (SMAs). This suggests potential short-term weakness or consolidation. In contrast, the weekly and monthly timeframes display bullish Super Trend signals, with the price trading above these indicators, indicating a stronger underlying uptrend on longer durations. Recent active weekly patterns include a Hammer and an Inside Bar, which can sometimes signal trend continuation or reversal.

The stock is currently positioned near its nearest resistance level at ₹3444.07, approximately 0.11% above the current price. Key support is observed around ₹3405.03, about 1.03% below the current price. The stock has experienced an extreme volume anomaly on September 10, 2026, with a significant price increase and a volume ratio of 3.78, indicating heightened activity. The annualized volatility stands at 0.42, with a current drawdown of -0.07 and a maximum drawdown of -0.18, suggesting moderate risk.

Key conditions to monitor include a sustained break above the ₹3444.07 resistance level, which could reinforce the longer-term bullish trend. Conversely, a decisive move below the ₹3405.03 support level, especially on increased volume, might signal a weakening of the weekly and monthly uptrends and a potential continuation of the daily bearish signal.

- The stock closed at ₹3440.3 on September 18, 2026.
- Daily timeframe shows a bearish Super Trend signal, while weekly and monthly timeframes are bullish.
- Nearest resistance is observed at ₹3444.07 (0.11% above current price).
- Nearest support is observed at ₹3405.03 (1.03% below current price).
- Watch for a break above ₹3444.07 or below ₹3405.03 for potential trend confirmation or reversal.

- Hammer
- Inside Bar
- Harami
- Bullish Engulfing Reversal
- Doji

### News Context

Acutaas Chemicals was highlighted in market commentary on September 18, 2026, with one report suggesting a 'buy' at ₹3,315, anticipating upward movement towards ₹4,000. This commentary noted the stock had reached a record high of ₹3,735 in early July before consolidating, with a support base identified between ₹3,000 and ₹3,050. The company was also listed among several others scheduled to trade ex-dividend on September 17, 2026.

- On September 18, 2026, Acutaas Chemicals was recommended as a 'buy' at ₹3,315 with an expectation of reaching ₹4,000, according to market commentary.
- The same commentary on September 18, 2026, noted the stock's consolidation after reaching a record high of ₹3,735 in early July, with support identified at the ₹3,000-₹3,050 price band.
- Acutaas Chemicals was scheduled to trade ex-dividend on September 17, 2026.

- Sensex today | Stock Market Live: Stock to buy today: Acutaas Chemicals (₹3,315.60)
- Stock to buy today: Acutaas Chemicals (₹3,315.60)
- IRCON International, MSTC, Sansera Engineering, Sunteck Realty among stocks to turn ex-dividend on September 17

### What Changed

Acutaas Chemicals (NSE: ACUTAAS) has seen recent discussion around its stock performance, with one report on 2026-09-18 noting a previous record high of ₹3,735 reached in early July. Following this peak, the stock reportedly lost momentum and entered a consolidation phase, though the uptrend is considered intact as long as the ₹3,000-3,050 price band acts as support. The current price on 2026-09-18 was ₹3,440.3, an increase from the previous price of ₹3,315.1. Another report from the same date suggested an expectation of upward momentum towards ₹4,000.

What remains unchanged is the company's profile as Acutaas Chemicals listed on the NSE.

- On 2026-09-18, Acutaas Chemicals' stock was trading at ₹3,440.3, up from ₹3,315.1 previously.
- A report on 2026-09-18 mentioned the stock reached a record high of ₹3,735 in early July.
- Following the July high, the stock reportedly entered a consolidation phase, with the ₹3,000-3,050 price band identified as support.
- External commentary on 2026-09-18 suggested potential upward momentum towards ₹4,000.

- Sensex today | Stock Market Live: Stock to buy today: Acutaas Chemicals (₹3,315.60)
- Stock to buy today: Acutaas Chemicals (₹3,315.60)

### Official Filings

Acutaas Chemicals Limited has announced several developments impacting its operational capacity and strategic initiatives. On August 22, 2026, the company's board approved a significant capital expenditure of up to ₹212 crore for a new plant in Gujarat, intended to produce electronic grade chemicals with a proposed capacity of up to 81,000 metric tons per annum, targeted for completion by the end of fiscal year 2027-28. This expansion is supported by an incentive package under the Electronics Components Manufacturing Scheme (ECMS) for its Electrolyte Additives business in Jhagadia, Gujarat, where the cumulative project investment is ₹256.47 crore, with ₹119.12 crore eligible for incentives up to 25% during the benefit period ending FY 2030-31. Further enhancing its R&D capabilities, Acutaas inaugurated a new Pilot Plant at its Sachin, Surat facility on September 4, 2026, designed to support new product trials and validations, including a dedicated area for Occupational Exposure Band (OEB) 4 containment for developing high potency intermediates. The company also reported on September 10, 2026, that the Patent Office of India granted it a 20-year process patent for 'A PROCESS FOR PREPARING 2,4-DIMETHYLTHIOPHENOL,' effective from September 21, 2017, bringing its total granted patents to 11. Additionally, a step-down subsidiary, Indichem Inc., inaugurated a semiconductor chemicals manufacturing plant in Gongju, South Korea, on August 28, 2026, with Acutaas Advance Material Limited (AAML) holding a 75% stake and having invested approximately ₹200 crore in the venture.

- On August 22, 2026, the board approved a capital expenditure of up to ₹212 crore for a new electronic grade chemicals plant in Gujarat, with a target capacity of 81,000 MT per annum by the end of FY 2027-28.
- On August 18, 2026, the company received approval for an ECMS incentive package for its Electrolyte Additives business in Gujarat, with a project investment of ₹256.47 crore and ₹119.12 crore eligible for incentives.
- A new Pilot Plant for R&D and new product trials was inaugurated on September 4, 2026, at the Sachin, Surat facility.
- On September 10, 2026, Acutaas Chemicals Limited was granted a 20-year process patent for 'A PROCESS FOR PREPARING 2,4-DIMETHYLTHIOPHENOL', increasing its total granted patents to 11.
- On August 28, 2026, a step-down subsidiary, Indichem Inc., inaugurated a semiconductor chemicals manufacturing plant in South Korea, involving an investment of approximately ₹200 crore by AAML.

- Acutaas Chemicals Limited has informed the Exchange about General Updates |SUBJECT: General Updates
- Acutaas Chemicals Limited has informed the Exchange about General Updates |SUBJECT: General Updates
- Acutaas Chemicals Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- Acutaas Chemicals Limited has informed the Exchange regarding a press release dated August 28, 2026, titled "Acutaas Chemicals step-down subsidiary Indichem inaugurates Semiconductor Materials Plant at Gongju, The Republic of Korea". |SUBJECT: Press Release
- Acutaas Chemicals Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- Acutaas Chemicals Limited has informed the Exchange about General Updates |SUBJECT: General Updates
- ACUTAAS CHEMICALS LIMITED has informed the Exchange about Capacity addition (Sub-para 3-Para B) |SUBJECT: Capacity addition (Sub-para 3-Para B)
- Acutaas Chemicals Limited has informed the Exchange about General Updates |SUBJECT: General Updates
- ACUTAAS CHEMICALS LIMITED has informed the Exchange about Key licenses/regulatory approvals (Sub-para 12-Para B) |SUBJECT: Key licenses/regulatory approvals (Sub-para 12-Para B)
- Acutaas Chemicals Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates

### Fundamentals

Acutaas Chemicals has demonstrated a significant upward trajectory in its financial performance, with reported sales growing from ₹717 crore in FY2024 to a projected ₹1,339 crore by FY2026. This growth is accompanied by a substantial improvement in operating profit, which is expected to increase from ₹128 crore in FY2024 to ₹480 crore by FY2026. The company's operating profit margin (OPM) is also projected to expand considerably, from 18.0% in FY2024 to an anticipated 36.0% in FY2026. Earnings per share (EPS) have shown a strong recovery, rising from ₹5.80 in FY2024 to a projected ₹43.51 by FY2026.

Financially, the company's balance sheet shows a notable increase in Fixed Assets from ₹427 crore in FY2024 to a projected ₹745 crore by FY2026, alongside a significant rise in Construction Work in Progress (CWIP) from ₹125 crore to ₹332 crore over the same period. This expansion is financed by a substantial increase in borrowings, which rose from ₹217 crore in FY2024 to a projected ₹13 crore in FY2025, and then to ₹36 crore in FY2026, alongside a growing equity base. Cash flow from operations has also seen a positive trend, increasing from ₹125 crore in FY2024 to a projected ₹292 crore in FY2026. However, free cash flow has remained negative, projected to be ₹-36 crore in FY2026, indicating that operational cash generation is not yet sufficient to cover investing activities.

Key monitoring areas include the continued expansion of sales and operating margins, the management of borrowings and their impact on finance costs, and the generation of positive free cash flow. The increasing investments in fixed assets and CWIP suggest ongoing capital expenditure, which will be important to track for future returns. Shareholding patterns show a decrease in promoter holding from 39.91% in March 2024 to a projected 32.66% by March 2026, while FIIs and DIIs have increased their stakes.

- Sales are projected to grow from ₹717 crore in FY2024 to ₹1,339 crore in FY2026.
- Operating Profit is expected to increase from ₹128 crore in FY2024 to ₹480 crore in FY2026, with OPM projected to rise from 18.0% to 36.0%.
- EPS is forecasted to rise from ₹5.80 in FY2024 to ₹43.51 in FY2026.
- Fixed Assets are projected to increase from ₹427 crore in FY2024 to ₹745 crore by FY2026, with CWIP rising from ₹125 crore to ₹332 crore.
- Promoter shareholding is projected to decrease from 39.91% in March 2024 to 32.66% by March 2026.

### Bull Case

Acutaas Chemicals has demonstrated significant growth in key financial metrics. Over the last five years, the company has achieved a compounded sales growth of 32% and a compounded profit growth of 46%. This trend has accelerated in the Trailing Twelve Months (TTM) period, with sales growing by 41% and profits by 104%. The company's operational efficiency is reflected in its cash flow from operations, which increased from ₹15 crore in March 2019 to ₹27 crore in March 2020. Free cash flow also turned positive, moving from -₹7 crore in March 2019 to ₹6 crore in March 2020. The balance sheet shows an increase in reserves from ₹72 crore in March 2019 to ₹101 crore in March 2020, alongside a rise in fixed assets from ₹79 crore to ₹85 crore, indicating investment in operational capacity. Concurrently, total liabilities decreased from ₹213 crore to ₹232 crore, while total assets grew from ₹213 crore to ₹232 crore.

- Compounded sales growth reached 32% over 5 years and 41% on a TTM basis.
- Compounded profit growth was 46% over 5 years and 104% on a TTM basis.
- Cash flow from operations increased from ₹15 crore (Mar 2019) to ₹27 crore (Mar 2020).
- Free cash flow improved from -₹7 crore (Mar 2019) to ₹6 crore (Mar 2020).
- Reserves grew from ₹72 crore (Mar 2019) to ₹101 crore (Mar 2020).

- Sensex today | Stock Market Live: Stock to buy today: Acutaas Chemicals (₹3,315.60)
- Stock to buy today: Acutaas Chemicals (₹3,315.60)
- IRCON International, MSTC, Sansera Engineering, Sunteck Realty among stocks to turn ex-dividend on September 17

### Bear Case

Acutaas Chemicals shows an increase in borrowings from ₹54 crore in March 2019 to ₹59 crore in March 2020. Concurrently, its Capital Work-In-Progress (CWIP) significantly rose from ₹2 crore to ₹12 crore over the same period, indicating increased investment in ongoing projects. While total assets grew to ₹232 crore in March 2020 from ₹213 crore in March 2019, this expansion was accompanied by a rise in total liabilities. The company's cash flow from financing activities was ₹0.0 in March 2020, a decrease from ₹6.0 in March 2019, suggesting a reduced reliance on external financing for that period. The daily trend analysis indicates a bearish supertrend direction as of September 18, 2026, with an ADX of 14.93, suggesting a lack of strong directional momentum.

- Borrowings increased to ₹59 crore in March 2020 from ₹54 crore in March 2019.
- Capital Work-In-Progress (CWIP) rose to ₹12 crore in March 2020 from ₹2 crore in March 2019.
- Cash from financing activities decreased to ₹0.0 in March 2020 from ₹6.0 in March 2019.
- The daily supertrend direction was bearish as of September 18, 2026.

- Sensex today | Stock Market Live: Stock to buy today: Acutaas Chemicals (₹3,315.60)
- Stock to buy today: Acutaas Chemicals (₹3,315.60)
- IRCON International, MSTC, Sansera Engineering, Sunteck Realty among stocks to turn ex-dividend on September 17

### FAQs

**What has been the recent trend in Acutaas Chemicals' sales and profit growth?**

Acutaas Chemicals has shown strong growth in both sales and profits. Over the last five years, compounded sales growth was 32%, and compounded profit growth was 46%. In the Trailing Twelve Months (TTM) period, sales growth accelerated to 41%, and profit growth significantly increased to 104%.

**What are the key financial changes in Acutaas Chemicals' balance sheet between March 2019 and March 2020?**

Between March 2019 and March 2020, Acutaas Chemicals saw several balance sheet changes. Borrowings increased from ₹54 crore to ₹59 crore. Capital Work In Progress (CWIP) rose substantially from ₹2 crore to ₹12 crore, while Fixed Assets grew from ₹79 crore to ₹85 crore. Reserves increased from ₹72 crore to ₹101 crore. Total Assets grew from ₹213 crore to ₹232 crore, with Total Liabilities also increasing from ₹213 crore to ₹232 crore.

**What significant operational developments has Acutaas Chemicals announced recently?**

Acutaas Chemicals has announced several key developments. On September 10, 2026, the company was granted a 20-year process patent for 'A PROCESS FOR PREPARING 2,4-DIMETHYLTHIOPHENOL', bringing its total granted patents to 11. On September 4, 2026, a new state-of-the-art Pilot Plant was inaugurated at Unit 1 in Sachin, Surat, designed to support R&D for new product trials and validations, including a dedicated area for Occupational Exposure Band (OEB) 4 containment. Furthermore, on August 28, 2026, its step-down subsidiary Indichem Inc. inaugurated a semiconductor chemicals manufacturing plant in Gongju, South Korea.

**What is the recent technical outlook for Acutaas Chemicals' stock?**

As of September 18, 2026, the stock's daily trend indicators suggest a mixed picture, with some moving averages showing upward momentum while the Supertrend direction is bearish. However, the monthly and weekly trends are bullish, with strong ADX readings and bullish Supertrend directions. The stock is trading near its nearest resistance level of ₹3444.07, with support identified around ₹3405.03.

- Sensex today | Stock Market Live: Stock to buy today: Acutaas Chemicals (₹3,315.60)
- Stock to buy today: Acutaas Chemicals (₹3,315.60)
- IRCON International, MSTC, Sansera Engineering, Sunteck Realty among stocks to turn ex-dividend on September 17
- Acutaas Chemicals Limited has informed the Exchange about General Updates |SUBJECT: General Updates
- Acutaas Chemicals Limited has informed the Exchange about General Updates |SUBJECT: General Updates
- Acutaas Chemicals Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- Acutaas Chemicals Limited has informed the Exchange regarding a press release dated August 28, 2026, titled "Acutaas Chemicals step-down subsidiary Indichem inaugurates Semiconductor Materials Plant at Gongju, The Republic of Korea". |SUBJECT: Press Release
- Acutaas Chemicals Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
## Technical analytics

- As of: 2026-09-18
- Daily trend: Weak Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹3,321.03
- Risk regime: Price Risk Requires Attention

### Support levels
- 3341.9
- 3138
- 3100.6

### Resistance levels
- 3488
- 3720

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +3.78% |
| return_10 | +7.48% |
| return_1m | +1.44% |
| return_1y | +133.87% |
| return_20 | +7.16% |
| return_3m | +9.69% |
| return_5 | -0.32% |
| return_6m | +52.37% |
| return_since_start | 2.0594041796353935 |
| return_ytd | +96.50% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -17.53% |
| annualized_volatility | +42.14% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Sharp Sequential Decline from Record Peak, but Year-Over-Year Growth Remains Strong

Acutaas Chemicals reported a sharp drop in revenue and profit in the first quarter of FY2026‑27, following an exceptionally strong previous quarter. Despite the sequential decline, both the top and bottom lines remained significantly higher than the same quarter a year ago. The results reflect a pullback from record levels, while year‑over‑year growth stayed substantial.

## Revenue

Revenue from operations fell to ₹329.67 crore in Q1 FY2026‑27, down 23.8% from ₹432.75 crore in Q4 FY2025‑26. The Q1 figure was lower than both Q4 and the ₹393.18 crore recorded in Q3, but higher than the ₹306.20 crore in Q2 and ₹207.24 crore in Q1 of the prior year. Compared with the same quarter a year ago, revenue rose 59.1%. The sequential decline interrupted a run of four consecutive quarterly revenue increases.

## Profitability

Profit before tax (PBT) declined 43.5% sequentially, from ₹183.80 crore in Q4 to ₹103.91 crore in Q1. Net profit from continuing operations fell 44.2%, from ₹134.28 crore to ₹74.99 crore. On a year‑over‑year basis, PBT increased 78.9% and net profit rose 70.4%.

The PBT margin narrowed to 31.5% in Q1, compared with 42.5% in the previous quarter, as profit fell more sharply than revenue. Year over year, however, the PBT margin improved from 28.0% in Q1 of the prior year.

## Expenses

Finance costs were little changed at ₹1.14 crore, compared with ₹1.19 crore in Q4. Other expenses fell 25.7% to ₹38.28 crore, roughly in line with the revenue decline. In the current quarter, the company reported cost of materials consumed of ₹165.77 crore, employee benefit expense of ₹39.57 crore, and depreciation of ₹9.82 crore.

## Earnings Per Share and Tax

Basic earnings per share (EPS) dropped to ₹9.07 from ₹16.09 in Q4, a decline of 43.6%. Diluted EPS followed a similar pattern, falling to ₹9.04 from ₹16.04. Year over year, basic EPS rose 67.6% from ₹5.41. The effective tax rate increased to 27.8% in Q1, up from 26.9% in Q4 and 24.2% in the same quarter a year ago. No exceptional items or discontinued operations were reported.

## Key Takeaway

Q1 FY2026‑27 marked a sharp sequential pullback from the record Q4, but year‑over‑year growth in revenue, profit, and EPS remained strong. The PBT margin compressed compared with the previous quarter, while improving relative to the same quarter last year. The company’s Q1 performance, though well below the peak, still represents a substantial increase over the prior‑year period and sets the starting point for the current fiscal year.

### Ratios

## Official filings

- 2026-09-10 — Generic Announcement: Acutaas Chemicals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AMIORG_10092026180124_Patent_IntimationSWsigned.pdf)
- 2026-09-04 — Generic Announcement: Acutaas Chemicals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AMIORG_04092026120612_Reg30swsigned040926.pdf)
- 2026-08-31 — Generic Announcement: Acutaas Chemicals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AMIORG_31082026143724_NewspaperPublication310826swsigned.pdf)
- 2026-08-28 — Press Release: Acutaas Chemicals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AMIORG_28082026085329_Pressreleaseforupload.pdf)
- 2026-08-24 — Generic Announcement: Acutaas Chemicals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AMIORG_24082026172539_NewspaperPublicationswsigned.pdf)
- 2026-08-22 — Generic Announcement: Acutaas Chemicals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AMIORG_22082026173537_OutcomeBM220826swSigned.pdf)
- 2026-08-22 — Generic Announcement: Acutaas Chemicals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_PARA_B_19536_WebXMLFile_20260822_181845411.xml)
- 2026-08-18 — Generic Announcement: Acutaas Chemicals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AMIORG_18082026105321_ECMS_IntimationSWSigned.pdf)
- 2026-08-18 — Generic Announcement: Acutaas Chemicals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_PARA_B_19536_WebXMLFile_20260818_113610850.xml)
- 2026-08-08 — Generic Announcement: Acutaas Chemicals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AMIORG_08082026125422_ScheduleSWSigned.pdf)
- 2026-08-08 — Earnings Presentation: Acutaas Chemicals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_19536_WebXMLFile_20260808_163948070.xml)
- 2026-07-28 — Official Filing: ACUTAAS CHEMICALS LIMITED has disclosed the transcripts of its earnings conference call held on July 24, 2026. The transcripts were uploaded to the company's website on July 28, 2026, at 17:30:00, and are available via a provided weblink.
- 2026-07-28 — Official Filing: Acutaas Chemicals Limited (formerly Ami Organics Limited) held an earnings call on July 24, 2026, to discuss Q1 FY27 results. The company reported strong revenue growth of 59.1% year-over-year to INR329.7 crores, driven by its Advanced Pharmaceutical Intermediates segment which grew 76.5% to INR292.7 crores. The Specialty Chemicals segment revenue was INR37 crores, a 10.6% decrease year-over-year, due to phasing out commodity chemicals. The company successfully completed the trial run of its battery chemicals plant and commenced commercial supply, with demand described as unprecedented. Capital expenditure for Q1 FY27 was INR56 crores, primarily for the battery chemical project and a pilot plant. Acutaas Chemicals reaffirmed its full-year revenue growth guidance of 25% with stable margins. — [Official attachment](https://nsearchives.nseindia.com/corporate/AMIORG_28072026182421_TranscriptSWmergedsigned.pdf)
- 2026-07-25 — Official Filing: ACUTAAS CHEMICALS LIMITED has made an audio recording available on 2026-07-25, accessible via a provided URL. The recording relates to an event that occurred on 2026-07-24 at 17:00:00, with the recording itself uploaded on 2026-07-24 at 18:05:00.
- 2026-07-25 — Official Filing: Acutaas Chemicals Limited (formerly Ami Organics Limited) published its unaudited financial results for the quarter ended June 30, 2026, on July 25, 2026. The results, covering both standalone and consolidated figures, were published in the Financial Express newspapers. The company is complying with SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/AMIORG_25072026122622_NewspaperpublicationswSigned.pdf)
- 2026-07-24 — Official Filing: Acutaas Chemicals Limited's Board of Directors approved the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, on July 24, 2026. The company reported consolidated revenue from operations of ₹32,967.48 lakhs and a profit after tax of ₹7,499.27 lakhs for the quarter. Additionally, the company disclosed that its shareholding in subsidiary Acutaas Chemicals Electrolytes Private Limited diluted from 100% to 90% due to a preferential issue. A GST and Central Excise inspection occurred at their Surat facility from June 22-23, 2026, with no expected material impact. — [Official attachment](https://nsearchives.nseindia.com/corporate/AMIORG_24072026123226_FRsw2407.pdf)
- 2026-07-24 — Official Filing: Acutaas Chemicals Limited (formerly Ami Organics Limited) has released its investor presentation for the first quarter ended June 30, 2026. The company reported revenue of ₹3,297 million, EBITDA of ₹1,131 million, and PAT of ₹750 million for Q1 FY27. The company also highlighted its certification as a Great Place to Work and receipt of the Responsible Care certification from the Indian Chemical Council. Acutaas Chemicals Limited anticipates delivering 25% revenue growth for the full year with stable margins. — [Official attachment](https://nsearchives.nseindia.com/corporate/AMIORG_24072026130627_PresentationcoveringSWsigned.pdf)
- 2026-07-24 — Generic Announcement: Acuitas Chemicals Limited has made the recording of its earnings call, held on July 24, 2026, available on its website at www.acutaas.com, in compliance with SEBI regulations. This follows their prior intimation about the earnings call on July 20, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/AMIORG_24072026182328_Recordingsigned.pdf)
- 2026-07-24 — Official Filing: Acutaas Chemicals Limited reported its Q1 FY27 financial results for the quarter ended June 30, 2026. Revenue from operations was ₹3,297 million, a 59.1% increase year-over-year. Profit After Tax (PAT) was ₹750 million, up 70.4% year-over-year, with PAT margins at 22.7%. — [Official attachment](https://nsearchives.nseindia.com/corporate/AMIORG_24072026130025_PressRelease2407signed.pdf)
- 2026-07-20 — Official Filing: AcuTaas Chemicals Limited (formerly Ami Organics Limited) will host an earnings conference call on Friday, July 24, 2026, at 4:00 PM IST to discuss the company's unaudited financial results for the first quarter ended June 30, 2026. The call is organized by Nuvama Wealth Management and will feature management representatives from Acutaas Chemicals. — [Official attachment](https://nsearchives.nseindia.com/corporate/AMIORG_20072026114240_Intimationcall30062026Signed.pdf)
- 2026-07-20 — Official Filing: ACUTAAS CHEMICALS LIMITED will hold a board meeting on July 24, 2026, to consider its unaudited standalone and consolidated financial results for the quarter ended June 2026. The trading window for the company's securities will be closed from July 1, 2026, to July 26, 2026.
- 2026-07-10 — Official Filing: ACUTAAS CHEMICALS LIMITED (formerly Ami Organics Limited) has submitted a certificate for the quarter ended June 30, 2026, confirming that no securities were received for dematerialisation, confirmed, rejected, mutilated, or cancelled during this period. This compliance statement was issued on July 10, 2026, by their Registrar and Share Transfer Agent, MUFG Intime India Private Limited. — [Official attachment](https://nsearchives.nseindia.com/corporate/AMIORG_10072026161736_Reg74300626swsigned.pdf)
- 2026-07-02 — Generic Announcement: Acuitas Chemicals Limited's Nomination and Remuneration Committee approved the promotion of Mr. Anurag Shukla to General Manager Operations & Unit Head — Ankleshwar, designating him as Senior Management Personnel, effective July 2, 2026. Mr. Shukla, who joined the company in September 2021, has over 21 years of experience in pharmaceutical manufacturing and operations. — [Official attachment](https://nsearchives.nseindia.com/corporate/AMIORG_02072026202253_NRCoutcome02072026SWSigned.pdf)
- 2026-06-26 — Generic Announcement: ACUTAAS CHEMICALS LIMITED (formerly Ami Organics Limited) will close its trading window for designated persons and their relatives from July 1, 2026, until 48 hours after the declaration of its unaudited financial results for the first quarter ending June 30, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, to facilitate the consideration of these financial results. — [Official attachment](https://nsearchives.nseindia.com/corporate/AMIORG_26062026173741_ClosureofTWCswSIGNED.pdf)
- 2026-06-23 — Generic Announcement: The CGST & CE Anti-evasion Department, Surat, Gujarat, concluded its inspection/search at Acutaas Chemicals Limited's registered office and manufacturing unit on June 23, 2026. The company provided requested documents and clarifications, and no official document has been issued by the CGST department. There is no material impact on the company's financials, operations, or other activities. — [Official attachment](https://nsearchives.nseindia.com/corporate/AMIORG_23062026112246_IntimationSWSigned.pdf)

## News and market events

- 2026-09-18 — The Hindu: **Sensex today | Stock Market Live: Stock to buy today: Acutaas Chemicals (₹3,315.60)** — Sensex, Nifty, Share Prices LIVE: Stock to buy today: Acutaas Chemicals’ stock reached a record high of ₹3,735 in early July. However, it lost momentum after that. Although it did not reverse the trend, the scrip started to consolidate. The chart shows formation of a strong base at ₹3,050. The ₹3,000-3,050 price band is support, and as long as this level holds, the uptrend will remain intact. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-18th-september-2026/article71477821.ece)
- 2026-09-18 — The Hindu: **Stock to buy today: Acutaas Chemicals (₹3,315.60)** — Buy Acutaas Chemicals at ₹3,315; expect upward momentum towards ₹4,000 with strategic stop-loss adjustments. — [Source](https://www.thehindubusinessline.com/portfolio/technical-analysis/stock-to-buy-today-acutaas-chemicals331560/article71476506.ece)
- 2026-09-16 — BUSINESSTODAY: **IRCON International, MSTC, Sansera Engineering, Sunteck Realty among stocks to turn ex-dividend on September 17** — Excel Industries, Gujarat Fluorochemicals, IRCON International, Landmark Cars, MSTC, Sansera Engineering, Tamil Nadu Newsprint & Papers, Agarwal Industrial Corporation, Acutaas Chemicals, ex-dividend stocks, dividend stocks, September 17 ex-dividend, final dividend, dividend record date, highest dividend stocks — [Source](https://www.businesstoday.in/markets/stocks/story/ircon-international-mstc-sansera-engineering-sunteck-realty-among-stocks-to-turn-ex-dividend-on-september-17-555895-2026-09-16)
- 2026-09-11 — The Hindu: **Broker’s call: Acutaas Chem (Buy)** — JM Financial — [Source](https://www.thehindubusinessline.com/markets/brokers-call-acutaas-chem-buy/article71456506.ece)
- 2026-09-11 — Mint: **Stock recommendations for 11 September from MarketSmith India** — MarketSmith India reveals its top stock recommendations for today, 11 September. Get expert insights into the best-performing stocks to guide your investment decisions. — [Source](https://www.livemint.com/market/stock-market-news/stock-recommendations-for-11-september-from-marketsmith-india-11789042912558.html)
- 2026-09-10 — Mint: **Already up 137% in 1 year still JM Financial sees more upside in this stock | Check target price, shareholding pattern** — With a staggering 137% rise in the past year, Acutaas Chemicals continues to draw attention from investors. JM Financial recently reinstated a buy rating with a target price of  ₹3,800, indicating more potential growth. — [Source](https://www.livemint.com/market/stock-market-news/already-up-137-in-1-year-still-jm-financial-sees-more-upside-in-this-stock-check-target-price-shareholding-pattern-11789038627007.html)
- 2026-07-31 — Mint: **Top Gainers & Losers on 31 July: Bajaj Finance, Hyundai Motor, GAIL, Tata Motors, Redington among top gainers today** — Indian equities closed the last trading day of July with modest gains, driven by financial and auto stocks. The Nifty 50 rose 0.20% to 24,336, while Sensex advanced 0.21% to 78,091, reflecting positive market trends despite concerns over crude oil prices. — [Source](https://www.livemint.com/market/stock-market-news/top-gainers-losers-on-31-july-bajaj-finance-hyundai-motor-gail-tata-motors-redington-among-top-gainers-today-11785490241096.html)
- 2026-07-24 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty recovers 200 pts from lows; Brent slips below $99/bbl** — Sensex Today | Stock Market LIVE Updates: As we move into the last half of the week's trade, the market is looking mark a recovery from lows. The markets are under pressure again, as the bulls stare down the barrel of a weekly decline. The Nifty is down over 160 points, falling towards 23,600. The Nifty Bank is down over 4000 points, falling to 56,000. Shriram Fin, IndiGo and Eternal are the top laggards. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-brent-crude-tariffs-infosys-indigo-bob-textile-midcaps-share-price-liveblog-19952825.htm)
- 2026-07-24 — The Hindu: **Sensex today | Stock Market Live: Sensex off day's low, down 300 pts, Nifty above 23,750; Cipla, HCL Tech lead gainers** — Sensex, Nifty, Share Prices Live Updates: Rising crude oil prices, unwinding of yen trade, fresh US tariffs, weakening rupee hurts market sentiment — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-24th-july-2026/article71257579.ece)
- 2026-07-24 — Mint: **Trump's tariff policy: Abbott India, Ajanta Pharma to Alembic — pharma stocks crash up to 4%** — Pharma stocks dipped on July 24 after President Trump announced a phased tariff plan for imported generic medicines, raising concerns for Indian exporters. Abbott India led losses at 3.69%, prompting fears over the future of American production and long-term impacts on stocks. — [Source](https://www.livemint.com/market/stock-market-news/trumps-tariff-policy-abbott-india-ajanta-pharma-to-alembic-pharma-stocks-crash-up-to-4-11784869745089.html)

## Business profile

**Strategic vision:** Specialty chemical manufacturer for pharma, semiconductor, and battery sectors.

### Business segments
- **Advanced Pharmaceutical Intermediates:** Provides intermediates for medicines, produced in USFDA and PMDA-approved facilities, focusing on long-term, backward-integrated solutions.
- **Semiconductor Chemicals:** Manufactures ultra-pure chemicals, including semiconductor-grade photoresist chemicals, serving domestic and international markets.
- **Battery Chemicals:** Offers advanced materials for energy storage, including electrolyte additives, with scaling production capacity.
- **Commodity Chemicals:** Provides foundation-scale solutions for industrial applications including personal care, agriculture, coatings, and fine chemicals.
- **CDMO and CMO Services:** Offers structured service models for scaling complex chemistries, including development support, commercial-scale production, custom synthesis, and process development.

### Competitive strengths
- Domestic manufacturer of semiconductor-grade photoresist chemicals in India.
- First company in India (outside China) to commercially develop electrolyte additives.
- USFDA and PMDA-approved facilities for pharmaceutical intermediates.
- Long-term, backward-integrated solutions for supply chain resilience in pharmaceuticals.

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%
- [ASTERDM (Healthcare)](https://faxioms.com/stocks/asterdm) — -0.85%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/acutaas
Markdown representation: https://faxioms.com/stocks/acutaas?render=md